$3.30
0.15[4.76%]
At close: Apr 23
$3.30
0[0.00%]
After Hours: 7:15AM EDT
Ovid Therapeutics
(NASDAQ:OVID)Ovid Therapeutics Stock (NASDAQ:OVID), Analyst Ratings, Price Targets, Predictions
Ovid Therapeutics Inc has a consensus price target of $6.9, established from looking at the 7 latest analyst ratings. The last 3 analyst ratings were released from Wedbush, BTIG, and JonesTrading on April 5, 2024, December 21, 2023, and June 14, 2023. With an average price target of $8.33 between Wedbush, BTIG, and JonesTrading, there's an implied 152.53% upside for Ovid Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Wedbush
BTIG
JonesTrading
Ladenburg Thalmann
Citigroup
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Ovid Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/05/2024 | OVID | Buy Now | Ovid Therapeutics | $3.30 | 142.42% | Wedbush | Laura Chico | → $8 | Initiates | → Outperform | Get Alert |
| 12/21/2023 | OVID | Buy Now | Ovid Therapeutics | $3.30 | 233.33% | BTIG | Thomas Shrader | → $11 | Initiates | → Buy | Get Alert |
| 06/14/2023 | OVID | Buy Now | Ovid Therapeutics | $3.30 | 81.82% | JonesTrading | Sean Kim | → $6 | Initiates | → Buy | Get Alert |
| 05/02/2023 | OVID | Buy Now | Ovid Therapeutics | $3.30 | 112.12% | Ladenburg Thalmann | Michael Higgins | → $7 | Reiterates | → Buy | Get Alert |
| 08/29/2022 | OVID | Buy Now | Ovid Therapeutics | $3.30 | -24.24% | Citigroup | Yigal Nochomovitz | $2.4 → $2.5 | Maintains | Neutral | Get Alert |
| 05/20/2022 | OVID | Buy Now | Ovid Therapeutics | $3.30 | -27.27% | Citigroup | Yigal Nochomovitz | $4 → $2.4 | Maintains | Neutral | Get Alert |
| 08/25/2021 | OVID | Buy Now | Ovid Therapeutics | $3.30 | 21.21% | Citigroup | Yigal Nochomovitz | — | Maintains | Neutral | Get Alert |
FAQ
What is the target price for Ovid Therapeutics (OVID)?
The latest price target for Ovid Therapeutics (NASDAQ: OVID) was reported by Wedbush on April 5, 2024. The analyst firm set a price target for $8.00 expecting OVID to rise to within 12 months (a possible 142.42% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ovid Therapeutics (OVID)?
The latest analyst rating for Ovid Therapeutics (NASDAQ: OVID) was provided by Wedbush, and Ovid Therapeutics initiated their outperform rating.
When was the last upgrade for Ovid Therapeutics (OVID)?
There is no last upgrade for Ovid Therapeutics.
When was the last downgrade for Ovid Therapeutics (OVID)?
There is no last downgrade for Ovid Therapeutics.
When is the next analyst rating going to be posted or updated for Ovid Therapeutics (OVID)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ovid Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ovid Therapeutics was filed on April 5, 2024 so you should expect the next rating to be made available sometime around April 5, 2025.
Is the Analyst Rating Ovid Therapeutics (OVID) correct?
While ratings are subjective and will change, the latest Ovid Therapeutics (OVID) rating was a initiated with a price target of $0.00 to $8.00. The current price Ovid Therapeutics (OVID) is trading at is $3.30, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.